Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Agalsidase beta
Drug ID BADD_D00049
Description Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383]
Indications and Usage Agalsidase beta is indicated in the treatment of Fabry disease.[L16383]
Marketing Status approved; investigational
ATC Code A16AB04
DrugBank ID DB00103
KEGG ID D03228
MeSH ID C459420
PubChem ID 52918379
TTD Drug ID Not Available
NDC Product Code 58468-0040; 58468-0041
UNII RZD65TSM9U
Synonyms agalsidase beta | Fabrazyme
Chemical Information
Molecular Formula C50H78N4O14
CAS Registry Number 928659-70-5
SMILES CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O.CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3 =C(C=C2)OCCO3)O.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Auricular swelling04.01.01.002--Not Available
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Blood immunoglobulin G increased13.06.05.004--Not Available
Bradycardia02.03.02.002--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac output decreased13.14.02.001--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.12.02.002; 02.02.02.009; 08.01.08.019--Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Cough22.02.03.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages